カテゴリ： GlobalData, アメリカ, 企業調査

Cancer Genetics Inc (CGIX)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Cancer Genetics Inc (CGIX) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011371
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月22日
◆ページ数：66
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Cancer Genetics Inc (CGI) is a pharmaceutical company that offers diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGI’s clinical services include expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US.

Cancer Genetics Inc (CGIX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cancer Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Cancer Genetics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Cancer Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Cancer Genetics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Cancer Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Cancer Genetics Inc, Medical Equipment, Deal Details 11
Asset Purchase 11
Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11
Partnerships 13
Cancer Genetics Enters into Partnership with Mendel Health 13
Cancer Genetics Enters into Agreement with Lantern Pharma 14
Cancer Genetics Partners with ApoCell for ApoStream 15
Cancer Genetics Partners with H3 Biomedicine 16
Cancer Genetics Enters into Distribution Agreement with Sayre Therapeutics 17
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 18
Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 19
Equity Offering 20
Cancer Genetics Prices USD7 Million in Private Placement of Units 20
Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 21
Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 22
Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 23
Cancer Genetics Raises USD12 Million in Public Offering of Shares 24
Cancer Genetics Completes Public Offering Of Shares For US$46 Million 26
Cancer Genetic Announces Public Offering Of Common Stock For Up To US$50 Million 28
Cancer Genetics Completes Underwriters’ Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$16 Million 30
Cancer Genetics Completes IPO For US$7 Million 32
Cancer Genetics Inc – Key Competitors 34
Cancer Genetics Inc – Key Employees 35
Cancer Genetics Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 37
Recent Developments 38
Strategy And Business Planning 38
Apr 03, 2017: Cancer Genetics and Mendel Announce Strategic Partnership Enabling Artificial Intelligence in Precision Medicine to Drive Personalized Treatment and Accelerate Clinical Trial Matching for Cancer Care 38
Feb 05, 2016: Cancer Genetics Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota 39
Financial Announcements 40
Aug 14, 2017: Cancer Genetics Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise 40
May 11, 2017: Cancer Genetics Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability 42
Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update 44
Nov 10, 2016: Cancer Genetics Announces Strong Third Quarter with 68% Year over Year Revenue Growth and Highlights Path to Future Profitability 46
Aug 09, 2016: Cancer Genetics Reports Second Quarter 2016 Financial Results and Provides Company Updates 48
May 10, 2016: Cancer Genetics Announces 39% Revenue Increase and Provides Recent Company Highlights 50
Mar 10, 2016: Cancer Genetics Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update 52
Corporate Communications 53
Nov 27, 2017: Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors 53
Feb 22, 2017: Cancer Genetics to Receive $1.0 Million in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program 54
Jun 27, 2016: Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts as COO and Executive Vice President of Finance 55
Product News 56
Dec 11, 2017: Cancer Genetics Advances Understanding of Immune Response and Measurement in Lymphomas by Combining PD-L1 Expression Analysis With RNA Analysis 56
Oct 30, 2017: Cancer Genetics a Leader in Personalized Medicine – Launches AntigenID, Solidifying CGI’s Position as a Precision Oncology Leader in the Fast Growing, Rapidly-Evolving Field of Immuno-Oncology Therapy & Drug Development 57
Sep 20, 2017: Cancer Genetics Announces 25th Contract Win to Provide Testing & Diagnostic Services for Combination Immuno-Oncology Clinical Trial 58
Jun 02, 2017: Cancer Genetics to Present at the 7th Annual LD Micro Invitational 59
Mar 13, 2017: Cancer Genetics to Present at “A Future Without Cancer Conference” on Friday, March 17 60
Jan 21, 2016: Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, and Therapy Selection for Patients 61
Jan 06, 2016: Cancer Genetics to Present Results of Collaborative Renal Biopsy and Clear Cell Renal Cell Carcinoma Studies at the 2016 Genitourinary Cancer Symposium 62
Other Significant Developments 63
Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions 63
Jun 02, 2016: Cancer Genetics Partners with ArcherDX to Offer Archer NGS Assays as a Sequencing Service for Biotech and Pharma 64
May 04, 2016: Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech and Pharma Companies 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Cancer Genetics Inc, Medical Equipment, Key Facts, 2016 2
Cancer Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Cancer Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Cancer Genetics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Cancer Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Cancer Genetics Inc, Deals By Market, 2011 to YTD 2017 9
Cancer Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11
Cancer Genetics Enters into Partnership with Mendel Health 13
Cancer Genetics Enters into Agreement with Lantern Pharma 14
Cancer Genetics Partners with ApoCell for ApoStream 15
Cancer Genetics Partners with H3 Biomedicine 16
Cancer Genetics Enters into Distribution Agreement with Sayre Therapeutics 17
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 18
Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 19
Cancer Genetics Prices USD7 Million in Private Placement of Units 20
Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 21
Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 22
Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 23
Cancer Genetics Raises USD12 Million in Public Offering of Shares 24
Cancer Genetics Completes Public Offering Of Shares For US$46 Million 26
Cancer Genetic Announces Public Offering Of Common Stock For Up To US$50 Million 28
Cancer Genetics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$16 Million 30
Cancer Genetics Completes IPO For US$7 Million 32
Cancer Genetics Inc, Key Competitors 34
Cancer Genetics Inc, Key Employees 35
Cancer Genetics Inc, Other Locations 36
Cancer Genetics Inc, Subsidiaries 36
Cancer Genetics Inc, Joint Venture 37

★海外企業調査レポート[Cancer Genetics Inc (CGIX)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Bajaj Allianz Life Insurance Company Ltd：企業の戦略・SWOT・財務情報
    Bajaj Allianz Life Insurance Company Ltd - Strategy, SWOT and Corporate Finance Report Summary Bajaj Allianz Life Insurance Company Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Anteo Diagnostics Ltd (ADO)：企業の財務・戦略的SWOT分析
    Anteo Diagnostics Ltd (ADO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Islet Sciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Islet Sciences Inc (Islet Sciences) is a drug development company that develops medicines and technologies for the treatment of metabolic diseases. The company's pipeline products include immune modulating small molecule interleukin 12 inhibitors to address disorders associated with inflamma …
  • APR Applied Pharma Research SA-医療機器分野：企業M&A・提携分析
    Summary APR Applied Pharma Research SA (APR) is a healthcare company which focuses on the development and licenses of healthcare products for rare therapeutic areas. The company offers consumer health products, prescription healthcare products and therapeutic products. APR’s product pipeline portfol …
  • Kirby Corp (KEX)：企業の財務・戦略的SWOT分析
    Kirby Corp (KEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • AccentCare Inc：企業の戦略的SWOT分析
    AccentCare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Vattenfall AB：企業の戦略的SWOT分析
    Vattenfall AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • SpectraCure AB (SPEC)-製薬・医療分野：企業M&A・提携分析
    Summary SpectraCure AB (SpectraCure) is a healthcare technology company that develops different methods for treatment planning and laser light dose management for cancer treatment. The company develops and therapy system (PDT) commercializes photodynamic with IDOSE for tumors. Its IDOSE platform all …
  • Ubisoft Entertainment SA (UBI)：企業の財務・戦略的SWOT分析
    Ubisoft Entertainment SA (UBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • JBS S.A.：企業のM&A・事業提携・投資動向
    JBS S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JBS S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Toll Holdings Ltd：企業の戦略的SWOT分析
    Toll Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Capitol Health Ltd (CAJ)-医療機器分野：企業M&A・提携分析
    Summary Capitol Health Ltd (Capitol Health) is a medical device company that provides diagnostic imaging and related services. The company provides services such as bone densitomety, computer tomography, cone beam CT, CT angiography, doppler, echocardiography, fluoroscopy, general X-ray, magnetic re …
  • Venture Life Group Plc (VLG)：製薬・医療：M&Aディール及び事業提携情報
    Summary Venture Life Group Plc (Venture Life) is a consumer goods company that offers ageing population products. The groups product and pipeline comprise food supplements for lowering cholesterol and maintaining brain function, medical devices for improving minor aches and pains, dry eyes and itchy …
  • WAVE Life Sciences Ltd (WVE)：製薬・医療：M&Aディール及び事業提携情報
    Summary WAVE Life Sciences Ltd (WAVE Life Sciences), formerly WAVE Life Sciences Pte Ltd is a genetic medicine company that develops stereopure nucleic acid therapies. The company's pipeline products comprise multiple oligonucleotide modalities such as exon-skipping and single-stranded RNAi, and ant …
  • Sika AG (SIKA)：企業の財務・戦略的SWOT分析
    Sika AG (SIKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Diana S.A.S.：戦略・SWOT・企業財務分析
    Diana S.A.S. - Strategy, SWOT and Corporate Finance Report Summary Diana S.A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Municipal Energy Agency of Nebraska：発電所・企業SWOT分析
    Municipal Energy Agency of Nebraska – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • BioLamina AB-製薬・医療分野：企業M&A・提携分析
    Summary BioLamina AB (BioLamina) is a biotechnology company that focuses on the development, manufacture and distribution of cell culture reagents intended for culturing primary cells. The company offers a wide portfolio of chemically defined and xeno-free laminin proteins. Its product portfolio inc …
  • Sinochem Group Co Ltd：企業の戦略的SWOT分析
    Sinochem Group Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Esperite NV (ESP)：企業の財務・戦略的SWOT分析
    Esperite NV (ESP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆